Silo Pharma (NASDAQ: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices’ (AMD) AI Developer Program. The program provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources and a global developer community. The company stated that this participation is expected to accelerate the development, testing, optimization and deployment of its AI agent platform across consumer and enterprise applications.
QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding and workflow automation. According to Silo, involvement in the AMD AI Developer Program is anticipated to support platform performance, agent reliability and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses and enterprise customers.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
The announcement highlights Silo Pharma's expansion into AI technology through its subsidiary, leveraging AMD's resources to enhance QwikAgents' platform. This move could position the company to tap into the growing demand for AI-driven automation tools, potentially creating new revenue streams beyond its core biopharmaceutical focus. For more details, the full press release is available at https://ibn.fm/313SC.
Investors can find the latest news and updates relating to SILO in the company’s newsroom at https://ibn.fm/SILO.
